icad Inc ICAD
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ICAD is a good fit for your portfolio.
News
-
iCAD to Report First Quarter 2024 Financial Results on May 15, 2024
-
iCAD Showcases New ProFound Cloud, Enhanced ProFound Detection Workstation Features and New Strategic Partnerships at SBI Annual Symposium
-
iCAD and Densitas Partner to Enhance Precision Breast Health with Leading AI Solutions for Mammography Quality, Cancer Detection, and Risk Evaluation
-
iCAD’s ProFound AI Suite Uncovers Hidden Heart Disease Risk According to New Data Presented at American College of Cardiology Meeting
-
iCAD Partners with RAD-AID to Advance Breast Cancer Detection Using AI in Underserved Regions and Low- and Middle-Income Countries (LMICs)
-
iCAD Unveils ProFound Cloud, Enabling Interoperability and Access to Breast AI Solutions at Enterprise Scale
-
iCAD Releases Enhanced ProFound Detection Workstation Features to Streamline Mammogram Interpretation for Radiologists
-
iCAD Announces Fiscal Fourth Quarter and Full-Year 2023 Financial Results
Trading Information
- Previous Close Price
- $1.49
- Day Range
- $1.45–1.51
- 52-Week Range
- $1.05–3.97
- Bid/Ask
- $1.43 / $1.61
- Market Cap
- $38.74 Mil
- Volume/Avg
- 62,830 / 191,683
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.17
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
icad Inc is a medical technology company providing cancer detection and therapy solutions. The Company operates in one segment: Detection. The Detection segment include advanced image analysis and workflow solutions that enable healthcare professionals to serve patients by identifying pathologies, comprehensive range of high-performance, Artificial Intelligence and Computer-Aided Detection (CAD) systems and workflow solutions for 2D and 3D mammography, Magnetic Resonance Imaging and Computed Tomography. The company geographically operates in France, Belgium, Italy, Germany, Switzerland and All other.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 69
- Website
- https://www.icadmed.com
Valuation
|
Metric
|
ICAD
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.16 |
Price/Sales | 2.17 |
Price/Cash Flow | — |
Price/Earnings
ICAD
Financial Strength
|
Metric
|
ICAD
|
|---|---|
Quick Ratio | 4.16 |
Current Ratio | 4.40 |
Interest Coverage | −481.44 |
Quick Ratio
ICAD
Profitability
|
Metric
|
ICAD
|
|---|---|
Return on Assets (Normalized) | −14.77% |
Return on Equity (Normalized) | −21.19% |
Return on Invested Capital (Normalized) | −21.85% |
Return on Assets
ICAD
Medical Devices Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ABT
| Abbott Laboratories | Zjynwzdnt | Srrtpzr | $184.2 Bil | |
SYK
| Stryker Corp | Rdltjqgndg | Ppy | $125.1 Bil | |
MDT
| Medtronic PLC | Tvysdnrqm | Ydzcyf | $108.5 Bil | |
BSX
| Boston Scientific Corp | Tkzxphtl | Klhzbk | $107.1 Bil | |
DXCM
| DexCom Inc | Vrpgdtvbb | Ctvq | $50.8 Bil | |
EW
| Edwards Lifesciences Corp | Hpspmlnt | Yvdvqsz | $50.8 Bil | |
ZBH
| Zimmer Biomet Holdings Inc | Xqdnfyjlsr | Jlwz | $25.0 Bil | |
PHG
| Koninklijke Philips NV ADR | Lvmszfy | Mxpthsq | $24.3 Bil | |
ALGN
| Align Technology Inc | Gfxrcwj | Jszcvy | $21.7 Bil | |
PODD
| Insulet Corp | Zbsytvcx | Zqzjhh | $12.2 Bil |